. 2015 Nov 3;5(1):29–41. doi: 10.2217/lmt.15.33

Table 3. . Adverse events^† specifically associated with VEGF inhibitors occurring in patients with adenocarcinoma in either treatment arm in the LUME-Lung 1 study.

Adverse events	Nintedanib plus docetaxel (n = 320), n (%)		Placebo plus docetaxel (n = 333), n (%)
	*All grades*	*Grade ≥3*	*All grades*	*Grade ≥3*
Bleeding	35 (10.9)	4 (1.3)	37 (11.1)	5 (1.5)

Gastrointestinal perforation	1 (0.3)	1 (0.3)	1 (0.3)	1 (0.3)

Venous thromboembolism	9 (2.8)	3 (0.9)	4 (1.2)	2 (0.6)

Arterial thromboembolism	3 (0.9)	3 (0.9)	7 (2.1)	3 (0.9)

Hypertension	11 (3.4)	1 (0.3)	2 (0.6)	1 (0.3)

^†Defined according to Common Terminology Criteria for Adverse Events v3.0.

Data taken from [26].

Table 3. . Adverse events† specifically associated with VEGF inhibitors occurring in patients with adenocarcinoma in either treatment arm in the LUME-Lung 1 study.